A Pilot Study of the Safety, Efficacy, and Side Effects of Interventional Cryotherapy for the Eradication of Disease in the Pleural Space ("ICE PLS")
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- CSA Medical, Inc.
- Enrollment
- 3
- Locations
- 1
- Primary Endpoint
- To Reduce Tumor Burden in the Pleural Space, as Determined by Visual Inspection and Biopsy of the Treatment Sites 2-5 Days Post Treatment. Safety Endpoint Clinical and Radiographic Status at 30 Days Post CryoSpray Treatment and Adverse Events.
- Status
- Terminated
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety, efficacy, and side effects of the CryoSpray Ablation(TM) System (CSA(TM) System) to treat neoplastic lesions on the parietal pleural surface.
Detailed Description
The proposed study is a pilot study consisting of an estimated 10 subjects with biopsy-proven metastatic cancer in the parietal pleural surface treated with CryoSpray at dye marked metastatic foci. Initial treatment dosimetry will be up to 3 cycles of 10-40 second sprays. If necessary, dosimetry changes may occur after 3 subjects are treated and observed. It is unknown if dosimetry will need to be increased to enhance effectiveness. The PI may increase dosimetry by 1 cycle after each subject is treated and observed as a conservative approach to efficacy determination. If disease exists bilaterally, only one side will be sprayed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age
- •Deemed a candidate for cryotherapy based on physician physical or medical history review
- •Deemed operable based on institutional criteria
- •Able to sign informed consent
- •Documented lung or other visceral cancer with pleural involvement.
- •WBC \> 4,000/mm3, platelets \>100,000mm3
- •Physically well enough to undergo moderate sedation and pleuroscopy
- •Female patients must be HCG negative
- •There should be direct evidence of disease progression despite treatment in previously treated patients
Exclusion Criteria
- •Pregnant or nursing
- •Planning to sire a child while enrolled in the study
- •Known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines.
- •Refusal or inability to give consent.
- •Concurrent chemotherapy.
- •Medical contraindication or potential problem that would preclude study participation
- •Concurrent participation in other experimental studies
- •Uncontrolled coagulopathy or bleeding diathesis
- •Serious medical illness, including:
- •Uncontrolled congestive heart failure
Outcomes
Primary Outcomes
To Reduce Tumor Burden in the Pleural Space, as Determined by Visual Inspection and Biopsy of the Treatment Sites 2-5 Days Post Treatment. Safety Endpoint Clinical and Radiographic Status at 30 Days Post CryoSpray Treatment and Adverse Events.
Time Frame: 1 year
Secondary Outcomes
- To Determine if CryoSpray Causes a Pleurodesis Effect. To Determine if CryoSpray Affects Production of Malignant Effusion Within the Treated Pleural Cavity. To Determine if Pleural Cavity Treatment With CryoSpray is Dosimetry Dependent.(1 year)